Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 16.54 | 4.03% | 0.64 |
MRNS closed up 4.03 percent on Friday, March 5, 2021, on 1.44 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical MRNS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Slingshot Bullish | Bullish Swing Setup | 4.03% | |
| Upper Bollinger Band Walk | Strength | 4.03% | |
| Overbought Stochastic | Strength | 4.03% | |
| Upper Bollinger Band Touch | Strength | 4.03% | |
| New 52 Week Closing High | Bullish | 0.61% | |
| Pocket Pivot | Bullish Swing Setup | 0.61% | |
| Upper Bollinger Band Walk | Strength | 0.61% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Upper Bollinger Band Resistance | 1 day ago | |
| Up 3% | 1 day ago | |
| Up 2% | 1 day ago | |
| 60 Minute Opening Range Breakout | 2 days ago | |
| Up 1% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/09/2021
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Alcohols Ketones Seizure Seizures Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Alcohols Ketones Seizure Seizures Sedatives Fragile X Syndrome Pregnanes Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.14 |
| 52 Week Low | 4.16 |
| Average Volume | 335,515 |
| 200-Day Moving Average | 11.77 |
| 50-Day Moving Average | 13.65 |
| 20-Day Moving Average | 15.10 |
| 10-Day Moving Average | 15.47 |
| Average True Range | 0.93 |
| ADX | 30.42 |
| +DI | 24.31 |
| -DI | 13.67 |
| Chandelier Exit (Long, 3 ATRs ) | 14.07 |
| Chandelier Exit (Short, 3 ATRs ) | 15.91 |
| Upper Bollinger Band | 16.64 |
| Lower Bollinger Band | 13.56 |
| Percent B (%b) | 0.97 |
| BandWidth | 20.38 |
| MACD Line | 0.70 |
| MACD Signal Line | 0.58 |
| MACD Histogram | 0.1247 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.64 | ||||
| Resistance 3 (R3) | 18.42 | 17.51 | 18.29 | ||
| Resistance 2 (R2) | 17.51 | 16.97 | 17.62 | 18.17 | |
| Resistance 1 (R1) | 17.02 | 16.64 | 17.27 | 17.24 | 18.06 |
| Pivot Point | 16.11 | 16.11 | 16.23 | 16.22 | 16.11 |
| Support 1 (S1) | 15.62 | 15.57 | 15.87 | 15.84 | 15.02 |
| Support 2 (S2) | 14.71 | 15.24 | 14.82 | 14.91 | |
| Support 3 (S3) | 14.22 | 14.71 | 14.79 | ||
| Support 4 (S4) | 14.44 |
